Radient Pharmaceuticals Corporation fka RXPC

[Future Doc]

@ Gold

No one mentioned "respect" in regards to the journals. It is a fact that foreign journals and journals that have low impact factors are considered with less gravity then are US journals and journals with high impact factors.

Yes, I do think that the RECAF test is interesting and has merit as a potential for cancer screening as well. Yes, the false positives are an issue at this point in time without pre-screening. That is inarguable.

On a slightly different note, it does seem that RPC is gearing their product towards a more applicable market with this Mayo trial.